Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Arun J. Sanyal(Virginia Commonwealth University), Patricia R. Robuck(National Institute of Diabetes and Digestive and Kidney Diseases), James Tonascia(Johns Hopkins University), Joel E. Lavine(Columbia University), Aynur Ünalp(Johns Hopkins University), Mark L. Van Natta(Johns Hopkins University), Arthur J. McCullough(Cleveland Clinic), Jeanne M. Clark(Johns Hopkins University), Elizabeth M. Brunt(Washington University in St. Louis), Brent A. Neuschwander‐Tetri(Saint Louis University), Naga Chalasani(Indiana University – Purdue University Indianapolis), Kris V. Kowdley(Liver Institute Northwest), Jay H. Hoofnagle(National Institutes of Health), David E. Kleiner(National Institutes of Health), Nathan M. Bass(University of California, San Francisco), Anna Mae Diehl(Duke Medical Center)
Cited by 3,291
Related Papers
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
|Hepatology|2017|7.2k
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis
|Journal of Hepatology|1999|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k